In This Issue of JAMA

April 10, 2018 Volume 319, Number 14 Pages 1411-1520

Research

Health Risk Variation Within the United States

1444

Variation in the prevalence of risk factors can account for differences in health outcomes. The US Burden of Disease Collaborators analyzed published studies and data sources by age, sex, geography, and year and found that differences in health outcomes were attributable to substance use disorders, high body mass index, diet, and high fasting plasma glucose. In an Editorial, Koh and Parekh suggest that greater investment in public health and social programs could yield healthier behaviors and more supportive environments.

Editorial 1438

■ Author Audio Interview jama.com CME jamanetwork.com/learning

Long-Acting Muscarinic Antagonists for Persistent Asthma

147

Stepwise escalation in therapy is recommended for patients with persistent asthma despite daily use of inhaled corticosteroids. Sobieraj and colleagues conducted a systematic review and meta-analysis of 15 randomized clinical trials in 7122 patients with uncontrolled, persistent asthma and concluded that adding a long-acting muscarinic antagonist to inhaled corticosteroids was associated with a lower risk of asthma exacerbations. In an Editorial, Krishnan and Au call for an update to current guidelines on pharmacotherapies for persistent asthma.

Editorial 1441 Related Article 1485

CME jamanetwork.com/learning

Long-Acting β-Agonists for Persistent Asthma

1485

Single maintenance and reliever therapy is the use of a combination infialed corticosteroid and long-acting β -agonist as both controller and quick relief therapy for patients with asthma. In a systematic review and meta-analysis of 16 randomized clinical trials in 22748 patients with persistent asthma, Sobieraj and colleagues concluded that single maintenance and reliever therapy, compared with other controller and relief therapies, was associated with a lower risk of asthma exacerbations.

Editorial 1441 Related Article 1473

■ CME jamanetwork.com/learning

Humanities

Poetry and Medicine 1511 Washed Feet J Petrili

JAMA Revisited 1512 Hypnotism

Opinion

Viewpoint

1429 The Proposal to Lower P Value Thresholds to .005

1431 Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases 85 Graham, JR Mascola, and AS Fauci

1433 Driving Under the Influence of Cannabis: An Increasing Public Health Concern

JG Ramaekers

1435 Enforcing Federal Drug Laws in States Where Medical Marijuana Is Lawful

LO Gostin, JG Hodge Jr, and SA Wetter

A Piece of My Mind 1437 A Third Option

SD Agarwal

Editorial

1438 Toward a United States of Health: Implications of Understanding the US Burden of Disease HK Koh and AK Parekh

1441 Time to Converge FDA Decisions and Evidence Syntheses for Long-Acting Muscarinic Antagonists and SMART in Guidelines for the Treatment of Asthma JA Krishnan and DH Au

LETTERS

Research Letter

1505 Acute Malnutrition and Anemia Among Rohingya Children in Kutupalong Camp, Bangladesh E Leidman and Coauthors

Comment & Response

1506 Treatment Approaches for Malignant Pleural Effusion

1508 Fracking and Climate Change

1509 Diagnosing Acute Mountain Sickness

1510 Correction

Editor in Chief Howard Bauchner, MD 134 YEARS OF CONTINUOUS PUBLICATION

In This Issue of JAMA

April 10, 2018 Volume 319, Number 14 Pages 1411-1520

Clinical Review & Education

101

ael

nd

GENOMICS AND PRECISION HEALTH

Sequencing of Tumor DNA to Guide Cancer Therapy

Sequencing of tumor DNA can identify tumor-associated somatic mutations to predict treatment response, guide therapy selection, and serve as molecular markers for disease monitoring. In this JAMA Insights article, Spencer and Ley compare the utility and value of exome and gene panel sequencing.

Macerated Rash of the Neck and Axilla

1499





This JAMA Clinical Challenge by Haley and colleagues presents a 58-year-old man with a blistering intertriginous rash that worsened in the summer months. What would you do next?

Benralizumab for Severe Asthma With Eosinophilic Phenotype

Benralizumab is a humanized monoclonal antibody that binds to the interleukin-5 receptor to decrease eosinophilic airway inflammation. This Medical Letter on Drugs and Therapeutics discusses the efficacy and safety of benralizumab for patients with poorly controlled severe asthma and elevated eosinophil levels.



JAMA Patient Page 1520 Medications for Asthma

NEWS & ANALYSIS

Medical News & Perspectives

1423 A Day in the Life: Facing the Opioid Epidemic in Huntington, West Virginia

1425 Did a Sugar Called Trehalose Contribute to the Clostridium difficile Epidemic?

1427 Blotech Innovations

Patient-Derived Organoids Predict Cancer Treatment Response

Using Heart Pump Data to Manage Cardiogenic Shock

Personal Genomics and Cryptocurrency

1428 News From the CDC

Lasting Effects of Childhood TBI Risks of "Raw Water"

Online @ jama.com



Editor's Audio Summary

Howard Bauchner, MD. summarizes and comments on this week's issue.

JAMA Network Open

JAMA Network Open is now accepting research submissions from across all disciplines. Read more at sites jamanetwork. com/jamanetworkopen/for-authors.html.

Author Interview



AUDIO Christopher J. L. Murray, MD, DPhil, author of "The State of US Health: Burden of Diseases, Injuries, and Risk Factors Among US States, 1990-2016"

Just Published

Read the latest Viewpoints and research presented at important clinical meetings published online first at jamanetwork.com/ journals/jama/newonline.

Departments

1419 Staff Listing

1503 CME Questions

1513 Classified Advertising

1517 Journal Advertiser Index

1519 Contact Information

Instructions for Authors

jama.com/public

/Instructionsforauthors.aspx